

SUPPLEMENTAL INFORMATION

HIV infection is linked with reduced error-related default mode network suppression and poorer medication management abilities

Jessica S. Flannery¹, Michael C. Riedel², Taylor Salo¹, Ranjita Poudel¹, Angela R. Laird², Raul Gonzalez¹, and Matthew T. Sutherland¹

¹ Department of Psychology, Florida International University, Miami, FL

² Department of Physics, Florida International University, Miami, FL

SUPPLEMENTAL CONTENT

TABLES

- Table S1: Mental health status (pp. 2)
- Table S2: HIV status and immune system markers (pp. 3)
- Table S3: Plasma THC and metabolite levels (pp. 4)
- Table S4: Drug dependence (pp. 5)
- Table S5: Past month and lifetime drug use (pp. 6)
- Table S6: EAT trial type counts and percentages (pp. 7)
- Table S7: Cognitive control cluster coordinates (pp. 8)
- Table S8: Error awareness cluster coordinates (pp. 9)
- Table S9: Main effect of HIV cluster coordinates (pp. 10)

FIGURES AND LEGENDS

- Figure S1: Error awareness brain activity group effects. (pp. 11)
- Figure S2: Impact of cannabis use on brain activity. (pp. 12)

SUPPLEMENTAL REFERENCES

SUPPLEMENTAL TABLES**Table S1. Participant mental health status by group.**

	All Participants <i>n</i> =109	HIV+/CB+ <i>n</i> =32	HIV+/CB- <i>n</i> =27	HIV-/CB+ <i>n</i> =28	HIV-/CB- <i>n</i> =22	Group Effects (<i>p</i> 's)	
						HIV	CB
Major Depressive Episode (current)	12	4	3	2	3	0.8	0.7
Major Depressive Episode (past)	25	11	3	4	7	0.8	0.6

NOTE. Mental health status is reported as count of participants meeting criteria for a current or past Major depressive episode as assessed via the Structured Clinical Interview for DSM-5 Research Version (SCID-5-RV) [1]. Participants were excluded from the sample if they presented severe mental illnesses with psychotic or paranoid symptoms. Group effects were assessed with two Chi-square tests, one comparing the HIV+ versus HIV- groups and the other comparing the CB+ versus CB- groups. No group differences were detected for any measure when conducting these same analyses after excluding participants who did not meet task engagement quality control threshold (*n*=2: HIV+/CB+; *n*=2: HIV+/CB-; *n*=2: HIV-/CB+).

Table S2. Participant HIV status and immune system markers by group.

	All HIV+ Participants <i>n</i> =59	HIV+/CB+ <i>n</i> =32	HIV+/CB- <i>n</i> =27	Group Effects (<i>p</i> 's)
Disease Characteristics				
Years since HIV diagnosis	9.8 (9.2)	8.7 (8.1)	11.1 (10.3)	0.3
% with detectable viral load (>200 copies/mL)	64.4	62.5	66.7	0.6
% with AIDS diagnosis	13.6	15.6	11.1	0.6
Viral Load (copies of HIV RNA/mL)				
HIV-1 (Linear)	14,087.1 (54,905.1)	18,654.9 (66,374.6)	8,673.3 (37,628.1)	0.2
HIV-1 (Log ₁₀)	1.3 (1.7)	1.4 (1.8)	1.1 (1.5)	0.2
Lymphocyte Subsets (cells/uL)				
T Helper Cells (CD3+CD4+)	639.0 (304.4)	647.6 (275.3)	628.9 (340.9)	0.8
T Suppress./Cyt.(CD3+CB8+)	1,064.8 (552.3)	972.2 (426.0)	1,174.5 (664.1)	0.8

NOTE. Data are either expressed as mean (standard deviation) or as the percentage of participants. HIV-1 viral load assessed via the Abbott RealTime HIV-1 assay. Group effects were assessed with independent samples *t*-tests or Chi-square tests comparing HIV+ cannabis users versus nonusers. No group differences were detected for any measure when conducting these same analyses after excluding participants who did not meet task engagement quality control threshold (*n*=2: HIV+/CB+ and *n*=2: HIV+/CB-).

Table S3. Participant plasma THC and metabolite levels by group.

	All CB+ Participants <i>n</i> =60	HIV+/CB+ <i>n</i> =32	HIV-/CB+ <i>n</i> =28	Group Effects (<i>p</i> 's)
9-carboxy-THC (ng/mL)	717.3 (1,087.1)	853.1 (1,343.9)	562.1 (679.7)	0.3
THC/creatinine ratio (ng/mg)	596.8 (686.9)	592.0 (712.0)	602.6 (670.0)	0.9

NOTE. Data are expressed as mean (standard deviation). Group effects were assessed with an independent samples *t*-test comparing cannabis using participants that were HIV+ versus HIV-. No group differences were detected for any measure when conducting these same analyses after excluding the participant who did not meet task engagement quality control threshold (*n*=2: HIV+/CB+ and *n*=2: HIV-/CB+).

Table S4. Participant drug dependence status by group.

	All Participants <i>n</i> =109	HIV+/CB+ <i>n</i> =32	HIV+/CB- <i>n</i> =27	HIV-/CB+ <i>n</i> =28	HIV-/CB- <i>n</i> =22	Group Effects (<i>p</i> 's)	
						HIV	CB
% Cannabis (past month)	10.1	18.8	0	17.9	0	0.9	0.002
% Cannabis (lifetime)	18.3	25.0	3.7	35.7	4.5	0.4	<0.001
% Alcohol (lifetime)	11.9	9.4	7.4	17.9	13.6	0.2	0.6
% Cocaine (lifetime)	11.0	9.4	7.4	14.3	13.6	0.4	0.8
% Other stimulants (lifetime)	3.7	9.4	3.7	0	0	-	-
% Opiates (lifetime)	1.8	3.1	0	3.6	0	-	-
% Other sedatives (lifetime)	1.8	6.3	0	0	0	-	-
% Hallucinogens (lifetime)	1.8	6.3	0	0	0	-	-
% Other drug (lifetime)	1.8	3.1	0	3.6	0	-	-

NOTE. Drug dependence data are expressed as the percentage of participants meeting dependency criteria either ever (lifetime) or in the past month (past month), as defined in the Structured Clinical Interview for DSM-5 Research Version (SCID-5-RV) [1]. As current (past month) drug dependence was exclusionary criteria (except cannabis dependence in the CB+ groups), no participants met dependency criteria in the past month for any of the reported drugs. Group effects were assessed with two Chi-square tests, one comparing the HIV+ vs. HIV- groups and one comparing the CB+ vs. CB- groups. These analyses were not performed when data did not meet criteria for Chi-square tests (cells with <5 observations). No significant differences were detected for any measure when conducting these same analyses after excluding participants who did not meet task engagement quality control threshold (*n*=2: HIV+/CB+; *n*=2: HIV+/CB-; *n*=2: HIV-/CB+).

Table S5. Mean past month and lifetime participant drug use (times used).

	All Participants <i>n</i> =109	HIV+/CB+ <i>n</i> =32	HIV+/CB- <i>n</i> =27	HIV-/CB+ <i>n</i> =28	HIV-/CB- <i>n</i> =22	Group Effects		
						HIVxCB	HIV	CB
Cannabis (past month)	13.0 (14.0)	21.9 (10.7)	0	25.6 (9.2)	0	<i>p</i> =0.2	<i>p</i> =0.2	<i>p</i><0.001*
Cannabis (lifetime)	2,404.7 (3,356.9)	3,765.6 (3,488.9)	114.0 (427.7)	4,580.3 (3,733.1)	467.5 (1,423.3)	<i>p</i> =0.7	<i>p</i> =0.3	<i>p</i><0.001*
Alcohol (past month)	2.3 (3.6)	2.2 (2.7)	2.1 (4.1)	3.3 (4.6)	1.6 (2.7)	<i>p</i> =0.2	<i>p</i> =0.7	<i>p</i> =0.2
Alcohol (lifetime)	1,204.7 (1,644.2)	1,198.5 (1,634.7)	1,184.8 (1,689.7)	1,416.1 (1,537.1)	969.2 (1,807.6)	<i>p</i> =0.5	<i>p</i> =0.9	<i>p</i> =0.5
Cocaine (past month)	0.0 (0.1)	0.1 (0.2)	0	0	0	<i>p</i> =0.2	<i>p</i> =0.2	<i>p</i> =0.2
Cocaine (lifetime)	362.5 (1,186.0)	351.0 (1,021.0)	297.9 (1,026.4)	312.0 (833.0)	523.0 (1,860.8)	<i>p</i> =0.6	<i>p</i> =0.7	<i>p</i> =0.7
Nicotine (past month)	5.5 (11.3)	8.2 (13.3)	0.3 (1.5)	7.9 (13.1)	4.9 (10.8)	<i>p</i> =0.3	<i>p</i> =0.3	<i>p</i>=0.012*
Nicotine (lifetime)	2,081.9 (3,731.2)	2,765.7 (4,542.0)	981.1 (2,540.5)	2,366.3 (3,328.6)	2,076.3 (4,065.8)	<i>p</i> =0.3	<i>p</i> =0.6	<i>p</i> =0.2
Methamphetamine (past month)	0.0 (0.2)	0.1 (0.4)	0	0	0	<i>p</i> =0.4	<i>p</i> =0.4	<i>p</i> =0.4
Methamphetamine (lifetime)	25.0 (126.6)	52.7 (208.8)	27.6 (99.3)	10.4 (54.4)	0.05 (0.2)	<i>p</i> =0.8	<i>p</i> =0.2	<i>p</i> =0.5
Prescription stimulants (past month)	0.02 (0.2)	0	0	0.1 (0.4)	0	<i>p</i> =0.3	<i>p</i> =0.3	<i>p</i> =0.3
Prescription stimulants (lifetime)	22.7 (207.2)	72.8 (381.4)	0	5.2 (22.7)	0	<i>p</i> =0.4	<i>p</i> =0.4	<i>p</i> =0.3
Heroin (past month)	0	0	0	0	0	-	-	-
Heroin (lifetime)	6.6 (69.0)	0	0	25.8 (136.1)	0.05 (0.2)	<i>p</i> =0.3	<i>p</i> =0.3	<i>p</i> =0.3
Opiates (past month)	0	0	0	0 (0.2)	0	-	-	-
Opiates (lifetime)	17.8 (102.6)	25.8 (127.2)	0	39.3 (149.7)	0.6 (2.5)	<i>p</i> =0.7	<i>p</i> =0.7	<i>p</i> =0.1
Benzodiazepines (past month)	0	0	0	0.04 (0.2)	0	<i>p</i> =0.3	<i>p</i> =0.3	<i>p</i> =0.3
Benzodiazepines (lifetime)	34.1 (252.7)	112.9 (461.9)	0	2.9 (7.3)	1.1 (3.6)	<i>p</i> =0.3	<i>p</i> =0.3	<i>p</i> =0.2
Barbiturates (past month)	0	0	0	0	0	-	-	-
Barbiturates (lifetime)	6.5 (47.9)	22.1 (87.4)	0	0.04 (0.2)	0	<i>p</i> =0.2	<i>p</i> =0.2	<i>p</i> =0.2
Ecstasy (past month)	0	0	0	0	0	-	-	-
Ecstasy (lifetime)	27.6 (93.5)	59.3 (147.9)	0.5 (1.6)	39.1 (84.6)	0.1 (0.4)	<i>p</i> =0.6	<i>p</i> =0.6	<i>p</i>=0.007*
Inhalants (past month)	0.04 (0.3)	0.1 (0.5)	0	0	0	<i>p</i> =0.2	<i>p</i> =0.2	<i>p</i> =0.2
Inhalants (lifetime)	3.4 (17.0)	57.2 (166.1)	0.2 (1.0)	2.5 (12.3)	0	<i>p</i> =0.1	<i>p</i> =0.1	<i>p</i> =0.1
Ever injection drug use (count)	2	1	0	1	0	-	<i>p</i> =0.4	<i>p</i> =0.4

NOTE. Data are expressed as mean (standard deviation). Drug use was self-reported as the number of “times” using each drug in the given timeframe (past month or lifetime) via items selected from the National Survey on Drug Use and Health [2]. Group effects were assessed with either an HIVxCB ANOVA or Chi square tests. * *p* < 0.05. No significant differences were detected for any measure when conducting these same analyses after excluding participants who did not meet task engagement quality control threshold (*n*=2: HIV+/CB+; *n*=2: HIV+/CB-; *n*=2: HIV-/CB+).

Table S6. EAT trial type counts and percentages by sample (n=109, 103, or 86).

Trial Type Count	<i>n</i> =109		<i>n</i> =103		<i>n</i> =86	
	Mean ± SEM	Range	Mean ± SEM	Range	Mean ± SEM	Range
a) Go-correct	904.4 ± 15.6	275-1056	936.6 ± 9.3	588-1056	929.3 ± 10.9	588-1056
Go-error-omission	63.5 ± 14.7	0-720	29.2 ± 5.4	0-313	34.4 ± 6.3	0-313
b) NoGo-correct	115.7 ± 3.1	29-198	114.4 ± 3.1	29-198	114.6 ± 3.6	0-313
NoGo-error (commission)	97.3 ± 3.3	18-187	98.5 ± 3.2	18-187	97.7 ± 3.7	18-187
c) NoGo-error-aware	69.2 ± 3.1	0-134	71.9 ± 3.1	0-134	70.2 ± 3.2	3-122
NoGo-error-unaware	21.1 ± 2.5	0-148	20.9 ± 2.6	0-148	21.2 ± 2.3	3-97
NoGo-error no response	7.0 ± 1.4	0-123	5.8 ± 0.8	0-60	6.2 ± 0.9	0-60
d) NoGo-repeat-error	40.7 ± 1.8	8-94	40.9 ± 1.8	8-94	41.6 ± 2.0	8-94
NoGo-repeat-error-aware	24.9 ± 1.4	0-60	25.7 ± 1.4	0-60	25.2 ± 1.5	0-56
NoGo-repeat-error-unaware	12.5 ± 1.5	0-80	12.4 ± 1.6	0-80	13.3 ± 1.7	0-80
NoGo-repeat-error no response	3.3 ± 0.7	0-58	2.8 ± 0.4	0-34	3.1 ± 0.5	0-34
e) NoGo-Stroop-error	56.7 ± 1.9	10-99	57.6 ± 1.9	10-99	56.0 ± 2.2	10-99
NoGo-Stroop-error-aware	44.3 ± 2.0	0-82	46.2 ± 1.9	0-82	45.0 ± 2.0	2-82
NoGo-Stroop-error-unaware	8.6 ± 1.2	0-82	8.4 ± 1.3	0-82	8.0 ± 1.0	0-51
NoGo-Stroop-error no response	3.7 ± 0.7	0-65	3.0 ± 0.4	0-26	3.1 ± 0.4	0-26
Trial Type Percent	<i>n</i> =109		<i>n</i> =103		<i>n</i> =86	
	Mean ± SEM	Range	Mean ± SEM	Range	Mean ± SEM	Range
a) % Go-correct	93.5 ± 1.5	30.1-100	96.9 ± 0.6	65.3-100	96.4 ± 6.2	65.3-100
% Go-error-omission	6.5 ± 1.5	0-69.9	3.1 ± 0.6	0-34.7	3.7 ± 0.7	0-34.7
b) % NoGo-correct	54.5 ± 1.5	13.4-91.7	53.9 ± 1.5	13.4-91.7	54.2 ± 1.7	13.4-91.7
% NoGo-error (commission)	45.6 ± 1.5	8.3-86.6	46.1 ± 1.5	8.3-86.6	45.8 ± 1.7	8.3-86.6
c) % NoGo-error-aware	72.0 ± 2.5	0-100	73.5 ± 2.4	0-100	72.5 ± 2.3	3.2-96.9
% NoGo-error-unaware	21.7 ± 2.3	0-100	21.2 ± 2.3	0-100	21.8 ± 2.2	2.4-86.3
% NoGo-error no response	6.3 ± 0.9	0-74.1	5.4 ± 0.7	0-33.5	5.8 ± 0.7	0-33.5
d) % NoGo-repeat-error	<i>41.4 ± 1.6</i>	9.8-74.6	<i>40.9 ± 1.0</i>	19.8-74.6	<i>42.1 ± 1.0</i>	21.6-74.6
% NoGo-repeat-error-aware	64.6 ± 2.8	0-100	65.6 ± 2.8	0-100	63.1 ± 2.8	0-97.6
% NoGo-repeat-error-unaware	28.8 ± 2.7	0-100	28.6 ± 2.8	0-100	30.6 ± 2.8	0-97.6
% NoGo-repeat-error no response	6.6 ± 1.0	0-77.3	5.8 ± 0.7	0-42.5	6.3 ± 0.3	0-42.5
e) % NoGo-Stroop-error	<i>58.6 ± 1.7</i>	25.4-80.2	<i>59.1 ± 1.0</i>	25.4-80.2	<i>57.9 ± 1.0</i>	25.4-78.4
% NoGo-Stroop-error-aware	77.6 ± 2.4	0-100	79.3 ± 2.3	0-100	79.5 ± 2.1	12.5-100
% NoGo-Stroop-error-unaware	16.2 ± 2.1	0-100	15.5 ± 2.1	0-100	15.0 ± 1.8	0-75
% NoGo-Stroop-error no response	6.2 ± 0.9	0-71.4	5.2 ± 0.7	0-39.3	5.5 ± 0.7	0-39.3

NOTE. The *n*=103 sample was used for error-related brain and behavior assessments and excluded 6 participants from the total sample (*n*=109) that did not meet task performance criteria (more than 50% Go-errors). The *n*=86 sample was used for error-awareness-related brain and behavior assessments and excluded an additional 17 participants that did not commit at least 2 of each type of NoGo-error (aware and unaware). **Trial Type Count:** Rows in section a) do not add up to 1080 total Go trials because for every incorrect NoGo trial, an Awareness-trial, in which participants are instructed to press button-2 to indicate error awareness, takes the place of the Go trial immediately following the error. Further, four subjects only completed 4 out of the 6 task runs (720 total Go trials and 144 total NoGo trials) and one subject only completed 5 out of the 6 task runs (900 total Go trials and 180 total NoGo trials). This is also why rows in section b) do not add up to 216 total NoGo trials. **Trial Type Percent:** This section reports the **a)** percentage of correct and error Go trials out of total Go trials (adds up to 100%) and **b)** the percentage of correct and error NoGo trials out of the total NoGo trials (adds up to 100%). **c)** The percentage of aware, unaware and no response NoGo-errors out of all NoGo-errors (adds up to 100%). **d-e)** NoGo-repeat-errors and NoGo-Stroop-errors out of all NoGo errors (values italicized) such that these italicized values add up to 100%.

Table S7. Cognitive control success (inhibition) and failure (error) cluster coordinates. Regions showing greater activation during successful (NoGo-correct) and failed (NoGo-error) NoGo trials. Whole-brain, one-sample *t*-test (two-tailed, 3dTtest++), thresholded at $p_{\text{voxel-wise}}=1.0e^{-10}$, cluster extent: 20 voxels (arbitrarily chosen). $n=103$: 6 participants from the total sample ($n=109$) were excluded because they did not meet task performance criteria (more than 50% Go-errors).

	Region	Hemisphere	Center Coordinates (MNI, LPI)			Cluster Size (# of Voxels)
			X	Y	Z	
NoGo-Correct (C > E)						
1	Middle occipital gyrus	R	32	-79	15	625
2	Middle occipital gyrus	L	-29	-85	13	564
3	Cerebral white matter	L	-27	-24	33	236
4	Ventral striatum (putamen, nucleus accumbens)	R	22	11	-4	116
5	Paracentral gyrus (primary motor cortex, primary sensory cortex)	R	10	-30	65	104
6	Superior temporal gyrus	R	61	-15	2	64
7	Ventral striatum (putamen, nucleus accumbens)	L	-22	10	-6	49
8	Paracentral gyrus (primary motor cortex, primary sensory cortex)	L	-10	-31	64	45
9	Hippocampus (parahippocampus, amygdala)	R	25	-9	-18	43
10	Cerebral white matter	R	25	29	18	40
11	Hippocampus (parahippocampus, amygdala)	L	-27	-11	-17	33
12	Cerebral white matter	R	26	1	35	20
NoGo-Error (E > C)						
1	Postcentral gyrus/inferior parietal gyrus	L	-46	-27	54	814
2	SMA/Pre-SMA/superior, middle & medial frontal gyrus	B	-1	18	48	223
3	Cerebellum (culmen & dentate)	R	19	-55	-21	144
4	Anterior Insula/inferior frontal gyrus (IFG)	L	-46	18	-2	106
5	Thalamus	L	-10	-23	8	75
6	Precentral gyrus	L	-56	8	31	66
7	Cerebellum	R	17	-66	-54	57
8	Anterior Insula/inferior frontal gyrus (IFG)	R	53	18	0	41
9	Postcentral gyrus	R	61	-16	35	34
10	Middle insula/frontal opercular area	L	-45	-4	12	21

NOTE. Voxel size: 3.44 x 3.44 x 3.40 mm³. X: Left (-), Right (+); Y: Posterior (-), Anterior (+); Z: Inferior (-), Superior (+). Region labels come from the AFNI Talairach daemon atlas. See main text Figure 2A for graphical representation.

Table S8. Error awareness cluster coordinates. Regions showing greater activation during aware and unaware errors on NoGo trials. Whole-brain, one-sample *t*-test on NoGo-error: Aware minus NoGo-error: Unaware [A-U] contrast values ($p_{FWE-corrected} < 0.05$; $p_{\text{voxel-wise}} < 0.0001$, cluster extent: 7 voxels, 3dClustSim with spatial autocorrelation correction [3]). $n=86$: 23 participants from the total sample that either did not meet task performance criteria (more than 50% Go-errors) or did not commit at least 2 of each type of NoGo-error (aware and unaware) were excluded.

	Region	Hemisphere	Center Coordinates (MNI, LPI)			Cluster Size (# of Voxels)
			X	Y	Z	
Aware NoGo-errors (A > U)						
1	Postcentral, Precentral & inferior parietal gyrus	B	-38	25	72	2330
2	Cerebellum (vermis)	B	0	46	0	1440
3	Thalamus, putamen, posterior insula	R	0	39	4	586
4	Postcentral gyrus	R	45	39	65	487
5	Anterior insula/inferior frontal gyrus	R	59	-16	-3	179
6	Middle cingulate cortex	B	0	29	27	92
7	Ventral striatum (putamen, nucleus accumbens)	R	28	-2	-10	71
8	Superior parietal gyrus (precuneus)	R	7	77	55	45
9	Superior frontal gyrus	R	35	-54	31	39
10	Superior frontal gyrus	L	-34	-54	27	34
11	Middle posterior temporal gyrus	R	66	53	4	7
Unaware NoGo-errors (U > A)						
1	Middle frontal gyrus	R	28	-30	58	40
2	Inferior frontal gyrus (orbitalis)	R	42	-40	-17	18
3	Superior frontal gyrus	L	-24	-37	48	18
4	Inferior frontal gyrus (triangularis)	R	52	-26	14	12
5	Posterior cingulate cortex	R	11	56	14	11
6	Superior parietal gyrus (precuneus)	L	-48	-77	41	10
7	Posterior cingulate cortex	L	-10	-56	10	8

NOTE. Voxel size: 3.44 x 3.44 x 3.40 mm³. X: Left (-), Right (+); Y: Posterior (-), Anterior (+); Z: Inferior (-), Superior (+). Region labels come from the AFNI Talairach daemon atlas. See main text Figure 3A for graphical representation.

Table S9. Main effect of HIV serostatus cluster coordinates. Regions showing significant HIV main effects in a whole-brain, HIV x CB ANOVA (3dMVM) assessing cognitive-control/failure [C-E] activation maps ($p_{FWE-corrected} < 0.05$; $p_{voxel-wise} < 0.001$, cluster extent: 35 voxels). $n=103$: 6 participants from the total sample that did not meet task performance criteria (more than 50% Go-errors) were excluded.

	Region	Hemisphere	Center Coordinates (MNI, LPI)			Cluster Size (# of Voxels)
			X	Y	Z	
HIV main effect						
1	Medial prefrontal cortex (mPFC)	B	2	65	-2	39
2	Posterior cingulate cortex (PCC)	B	2	-51	29	36

NOTE. Voxel size: 3.44 x 3.44 x 3.40 mm³. X: Left (-), Right (+); Y: Posterior (-), Anterior (+); Z: Inferior (-), Superior (+). Region labels come from the AFNI Talairach daemon atlas. See main text Figure 4A for graphical representation.

SUPPLEMENTAL FIGURES AND LEGENDS




Figure S1. Error awareness brain activity in HIV-positive and HIV-negative groups. At the whole-brain level, no significant group effects on aware vs. unaware error [A-U] contrast images were detected. However, follow-up exploratory analyses on average [A] and [U] β coefficients extracted from PCC and mPFC ROI masks were conducted. **(A)** 3-way 2(HIV: positive vs. negative) x 2(CB: user vs. nonuser) x 2(AWARENESS: aware vs. unaware) ANOVAs were conducted separately for each ROI ($n=86$). Similar to the inhibition analyses reported in the main text (**main text Fig. 4A**), no significant HIV x CB interaction or CB main effects were observed; however, both the PCC ($F[1, 82] = 4.8, p=0.03$) and mPFC ($F[1, 82] = 7.6, p=0.007$) displayed a significant main effect of AWARENESS such that both regions displayed increased deactivation during aware errors relative to unaware errors. Further, consistent with the HIV main effect on brain deactivation during all errors (**main text Fig. 4A**), both regions also displayed a significant main effect of HIV such that, HIV- controls had increased deactivation in the PCC ($F[1, 82] = 7.0, p = 0.01$) and mPFC ($F[1, 82] = 10.4, p = 0.002$) compared to the HIV+ individuals. While these results indicate significantly less PCC and mPFC deactivation among the HIV+ group during both aware and unaware errors, the nonsignificant HIV x AWARENESS interactions ($p's > 0.6$) denote that both HIV- and HIV+ groups display a similar difference between aware and unaware error brain activity. **(B: $n=86$)** When assessing relations to task behavior we observed significant HIV by ERROR-COUNT interactions on PCC activity during aware errors ($F[1, 82] = 8.9, P_{Bonferroni-corrected} = 0.008$) similar to interaction effects on PCC activity during all errors that was reported in the main text (**main text Fig. 4C**). Follow-up conditional effects within each group indicated that, among HIV+ participants, increased PCC deactivation during aware errors was significantly associated with worsened cognitive control task performance (more NoGo-errors; $p=0.02$). **(C: $n=86$)** We also observed significant HIV by ERROR-COUNT interactions on PCC activity during and unaware errors ($F[1, 82] = 6.4, P_{Bonferroni-corrected} = 0.02$). Follow-up conditional effects within each group indicated that, among HIV- controls, increased PCC deactivation during unaware errors was associated with better cognitive control task performance (fewer NoGo-errors) whereas, among HIV+ participants, increased PCC activity during aware errors was associated with worsened cognitive control task performance. **(D: $n=86$)** We observed null effects of behavioral error awareness performance (%UNAWARE) on brain activity during aware errors ($p's > 0.1$). **(E: $n=86$)** We observed a significant main effect of awareness performance on mPFC brain activity during unaware errors such that decreased mPFC activity during unaware errors was linked to a higher percent of unaware errors ($F[1, 82] = 5.8, P_{Bonferroni-corrected} = 0.02$). Follow-up conditional effects within each group indicated that this main effect of error awareness performance on mPFC unaware activity was primarily displayed among HIV- controls ($p=0.01$).




Figure S2. Impact of chronic CB use on brain activity. To assess the impact of self-reported amount of CB used over the lifetime (LIFETIME-AMOUNT) and the impact of total times using CB (LIFETIME-USES) on HIV-associated functional brain alterations, we conducted exploratory HIV x LIFETIME-AMOUNT and HIV x LIFETIME-USES ANCOVAs on task-related β s (NoGo-error and NoGo-correct) averaged across voxels in ROIs displaying a significant main effect of HIV, among CB using participants ($n=55$). Past month amount of nicotine used and past month times using nicotine variables were included as covariates in these analyses. As the LIFETIME-AMOUNT and LIFETIME-USE variables were skewed to the right, both were \log_{10} transformed before conducting statistical tests. **(A)** During error-NoGo trials: among HIV-users, but not PLWH users, more times using CB over the lifetime ($\beta=1.2, t[24]=2.2, p=0.04$) was significantly linked to reduced deactivation in the mPFC. A similar, albeit nonsignificant pattern was observed for HIV- controls' amount of cannabis used over the lifetime ($\beta=0.7, t[24]=2.0, p=0.06$). **(B)** During correct-NoGo trials: among HIV- CB users, but not PLWH users, both times using CB over the lifetime ($\beta=1.5, t[24]=3.2, p=0.003$) and amount of CB used over the lifetime ($\beta=0.7, t[24]=2.3, p=0.03$) were significantly associated with reduced deactivation in the mPFC. No significant effects of LIFETIME-USES or LIFETIME-AMOUNT on PCC activity were observed.

SUPPLEMENTAL REFERENCES

1. First, M., et al., Structured clinical interview for DSM-5—Research version (SCID-5 for DSM-5, research version; SCID-5-RV). Arlington, VA. *American Psychiatric Association*, 2015
2. Substance, A. and H.S.A. Mental, National Survey on Drug Use and Health: Summary of Methodological Studies. 2014: p. 1971–2014
3. Cox, R.W., et al., FMRI Clustering in AFNI: False-Positive Rates Redux. *Brain Connect*, 2017. **7**(3): p. 152-171.10.1089/brain.2016.0475